What Proportion of Patients Fail to Achieve CDAI and SDAI Remission Based on Physician Global Assessment? an Analysis from the Prospective, Observational Registry

Michael Starr¹, Boulos Haraoui², Denis Choquette³, Louis Bessette⁴, Andrew Chow⁵, Philip Baer⁶, Suneil Kapur⁷, John Kelsall⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Francois Nantel¹², Allen J Lehman¹³, Brendan Osborne¹⁴, Karina Maslova¹³ and Cathy Tkaczyk¹⁴, ¹Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Credit Valley Rheumatology, Mississauga, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Balfour Medical Clinic, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Anti-TNF therapy and rheumatoid arthritis (RA)

Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Physician’s Global Assessment of Disease Activity (MDGA) is a measure that is frequently incorporated in disease activity indices which reflects the physician’s perception of disease activity in rheumatoid arthritis (RA). Objectives:The aim of this analysis was to assess the proportion of patients failing to achieve CDAI and SDAI remission based on MDGA in a real-world, routine clinical care setting in Canada. The aim of this analysis was to assess the proportion of patients failing to achieve CDAI and SDAI remission based on MDGA in a real-world, routine clinical care setting in Canada.

Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, ankylosing spondylitis (AS), or psoriatic arthritis (PsA) with infliximab (IFX) or golimumab (GLM). Eligible patients for this analysis included RA patients treated with IFX or GLM between 2005 and 2015. Modified versions of CDAI (mCDAI) and SDAI (mSDAI) were calculated by omitting MDGA from the formulas. Correlation of the standard and modified versions of each index was assessed with the Pearson’s correlation coefficient. ROC curve analysis was used to identify new thresholds for the modified versions of low disease activity (LDA) and remission. Cross-tabulations with the Chi-square test were used to assess the agreement between the standard and modified definitions of remission and LDA.

Results: A total of 1206 patients were included in the analysis with a mean (SD) age of 56.1 (13.4) years and a disease duration of 8.4 (8.9) years. A strong positive correlation was observed between the standard and modified versions of CDAI (r=0.99; P<0.001) and SDAI (r=0.99; P<0.001). Based on ROC analysis the new thresholds for remission and LDA were: CDAI (remission=2.65, LDA=10.05) and SDAI (remission=3.31, LDA=10.73). The proportion of patients achieving remission by both indices was 17.8% and 19.5%, patients not achieving remission by both indices was 75.3% and 74.4%, and patients achieving remission by the new thresholds only was 6.9% and 6.1%, for CDAI and SDAI, respectively. Cross-tabulation of the standard and modified thresholds showed that an additional 8.4% and 7.6% of non-remission cases for CDAI and SDAI, respectively, would be classified as remission with the modified definitions. Similarly, an additional 17.6% and 15.1% of non-LDA cases for CDAI and SDAI, respectively, would be classified as LDA.

Conclusion: The results of this analysis showed that MDGA could account for up to 8% of non-remission cases and up to 18% of non-LDA cases as measured by CDAI and SDAI. Omission of MDGA from these disease activity indices could have a significant impact on patient management in preventing overtreatment with DMARDs and biologics and avoiding unnecessary switching of DMARDs and biologics.

Disclosure: M. Starr, Janssen Inc., 5; B. Haraoui, Janssen Inc., 5; D. Choquette, Janssen Inc., 5; L. Bessette, Janssen Inc., 5; A. Chow, Janssen Inc., 5; P. Baer, Janssen Inc., 5; S. Kapur, Janssen Pharmaceutica Product, L.P., 5; J. Kelsall, Janssen Inc., 5; M. Teo, Janssen Inc., 5; E. Rampakakis, employee of JSS Medical Research, 3; E. Psaradellis, employee of JSS Medical Research, 3; F. Nantel, Employee of Janssen Inc., 3; A. J. Lehman, Employee of Janssen Inc., 3; B. Osborne, Employee of Janssen Inc., 3; K. Maslova, Employee of Janssen Inc., 3; C. Tkaczyk, Employee of Janssen Inc., 3.

To cite this abstract in AMA style:

Starr M, Haraoui B, Choquette D, Bessette L, Chow A, Baer P, Kapur S, Kelsall J, Teo M, Rampakakis E, Psaradellis E, Nantel F, Lehman AJ, Osborne B, Maslova K, Tkaczyk C. What Proportion of Patients Fail to Achieve CDAI and SDAI Remission Based on Physician Global Assessment? an Analysis from the Prospective, Observational Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/what-proportion-of-patients-fail-to-achieve-cdai-and-sdai-remission-based-on-physician-global-assessment-an-analysis-from-the-prospective-observational-registry/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-proportion-of-patients-fail-to-achieve-cdai-and-sdai-remission-based-on-physician-global-assessment-an-analysis-from-the-prospective-observational-registry/